Distinct Early Serological Signatures Track with SARS-CoV-2 Survival.
Atyeo C, Fischinger S, Zohar T, Slein MD, Burke J, Loos C, McCulloch DJ, Newman KL, Wolf C, Yu J, Shuey K, Feldman J, Hauser BM, Caradonna T, Schmidt AG, Suscovich TJ, Linde C, Cai Y, Barouch D, Ryan ET, Charles RC, Lauffenburger D, Chu H, Alter G. · 2020
Read Distinct Early Serological Signatures Track with SARS-CoV-2 Survival. by Atyeo C, Fischinger S, Zohar T, Slein MD, Burke J, Loos C, McCulloch DJ, Newman KL, Wolf C, Yu J, Shuey K, Feldman J, Hauser BM, Caradonna T, Schmidt AG, Suscovich TJ, Linde C, Cai Y, Barouch D, Ryan ET, Charles RC, Lauffenburger D, Chu H, Alter G. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7392190.txt.
Introduction
Atyeo and co-authors profile early antibody responses in hospitalized COVID-19 patients in Immunity. Why some patients recover while others die quickly was unknown. The team studied 22 hospitalized people in depth, then checked their conclusions in a larger group.
Total levels of virus-specific IgG did not separate the outcomes. Quality and target did. Survivors carried richer antibody responses against the spike protein, while patients who died showed stronger functional responses against the inner nucleocapsid protein. In other words, where antibodies aim matters more than how many there are. Early antibody signatures, the authors argue, point to the disease's trajectory and to the mechanisms that protect.
Catalog record
| CREATOR | Atyeo C, Fischinger S, Zohar T, Slein MD, Burke J, Loos C, McCulloch DJ, Newman KL, Wolf C, Yu J, Shuey K, Feldman J, Hauser BM, Caradonna T, Schmidt AG, Suscovich TJ, Linde C, Cai Y, Barouch D, Ryan ET, Charles RC, Lauffenburger D, Chu H, Alter G. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Distinct Early Serological Signatures Track with SARS-CoV-2 Survival By Caroline Atyeo, Stephanie Fischinger, Tomer Zohar, Matthew D. Slein, John Burke, Carolin Loos, Denise J. McCulloch, Kira L. Newman, Caitlin Wolf, Jingyou Yu, Kiel Shuey, Jared Feldman Published in: Immunity DOI: 10.1016/j.immuni.2020.07.020 ABSTRACT Summary As SARS-CoV-2 infections and death counts continue to rise, it remains unclear why some individuals recover from infection, whereas others rapidly progress and die. Although the immunological mechanisms that underlie different clinical trajectories remain poorly defined, pathogen-specific antibodies often point to immunological mechanisms of protection. Here, we profiled SARS-CoV-2-specific humoral responses in a cohort of 22 hospitalized individuals. Despite inter-individual heterogeneity, distinct antibody signatures resolved individuals with different outcomes. Although no differences in SARS-CoV-2-specific IgG levels were observed, spike-specific humoral responses were enriched among convalescent individuals, whereas functional antibody responses to the nucleocapsid were elevated in deceased individuals. Furthermore, this enriched immunodominant spike-specific antibody profile in convalescents was confirmed in a larger validation cohort. These results demonstrate that early antigen-specific and qualitative features of SARS-CoV-2-specific antibodies point to differences in disease trajectory, highlighting the potential importance of functional antigen-specific humoral immunity to guide patient care and vaccine development. INTRODUCTION SARS-CoV-2 is the newest coronavirus to cross into the human population (Wu et al., 2020b; Zhu et al., 2020). Millions of infections have been diagnosed (World Health Organization, 2020); however, the number of asymptomatic carriers is likely to far exceed these numbers (Li et al., 2020). Although the rapid spread of SARS-CoV-2, even during the asymptomatic phase of this infection, is alarming, more harrowing is our inability to predict disease trajectories among symptomatic individuals. In the absence of therapeutic agents and vaccines as countermeasures for this infection, there is an urgent need to begin to map the evolution of immunity to the pathogen to guide patient care and future immune interventions. Although antibody responses and T cells have been linked to disease resolution (Chen et al., 2020), and neutralizing antibodies have been demonstrated to block infection in small-animal models (Quinlan et al., 2020), little is known about the antibody features that are important for protection. Neutralizing antibodies develop in the majority of SARS- and MERS-infected individuals (Chang et al., 2005; de Wit et al., 2016); however, the virus can mutate to overcome these antibody responses (He et al., 2006; ter Meulen et al., 2006). Passive immunization studies with neutralizing and poorly neutralizing antibodies have shown protection in lethal MERS infection in mice (Zhao et al., 2015, 2017), suggesting that the neutralizing and extra-neutralizing functions of antibodies may play a critical role in control and resolution of disease. Moreover, recent studies have found lower neutralization titers in younger individuals and higher neutralization among individuals with severe disease (Wu et al., 2020a; Wang et al., 2020), suggesting that antibodies may depend on additional mechanisms to clear the virus. Antibody dynamics during the acute window of infection have been linked to differential outcomes across infections, including HIV (Tomaras and Haynes, 2009), influenza (Cobey and Hensley, 2017), and Ebola virus infection (Saphire et al., 2018). Specifically, selection of specific antibody subclasses and functional profiles is heavily influenced by inflammatory cascades and may not only forecast disease outcomes but also point to antibody mechanisms of action vital in early pathogen control and clearance. However, whether identifiable antibody functional profiles across SARS-CoV-2 antigen specificities evolve early following infection and track differentially with disease outcome is unknown. In this study, we assembled two cross-sectional sample sets of SARS-CoV-2-infected individuals at the time of hospital admission to begin to comprehensively profile the evolution of the early SARS-CoV-2 S-specific response and to define antibody features that are predictive of disease outcome. Through this analysis, we found that deceased and convalescent individuals present different humoral profiles, with a more spike (S)-focused response in individuals who convalesced and a stronger nucleocapsid (N)-specific response in individuals who succumbed to disease. RESULTS Early SARS-CoV-2 Antibody Profiles in Individuals Who Ultimately Convalesce or Pass Away Across infectious diseases, pathogen-specific antibodies can serve as biomarkers of infection and aid with early control and clearance of infection by blocking host-pathogen interactions and/or recruiting innate immune functions (Gunn and Alter, 2016). To investigate whether early SARS-CoV-2-specific humoral immune responses differ across individuals who ultimately recover or die from infection, a cohort of 22 hospitalized SARS-CoV-2-infected individuals, of whom 12 recovered and 10 died, was profiled. Samples were collected at hospital admission; all individuals were recruited within the first 20 days following symptom onset (Table 1; Figure S1) at the University of Washington, Seattle, one of the earlier epicenters in the United States (Holshue et al., 2020). Population demographics largely resemble those reported previously (Bhatraju et al., 2020), including elevated numbers of elderly men in the subset of individuals who died.Table 1Demographics of the SARS-CoV-2 Cohort from SeattleCharacteristicsConvalescent (n = 12)Deceased (n = 10)Female sex – no. (%)4 (33.3)3 (30)Age Range – No. (%)Younger than 493 (25)1 (10)50-594 (33.3)0 (0)60-694 (33.3)2 (20)70-790 (0)4 (40)80 and older1 (8.3)3 (30)Race or Ethnic Group – No (%)Asian2 (16.7)1 (10)Black0 (0)1 (10)White9 (75)7 (70)Missing data1 (8.3)1 (10)Median days from onset of symptoms to sample collection (IQR)a13.5 (15–8)7 (12–5)Median days spent in ICU (IQR)b13 (15–9)13(14–9)Median viral load (IQR)c28.3 (30.4–26.5)26.4 (28.375–21.725)Interventions – No./Total No. (%)Chloroquines6/12 (50)7/10 (70)Remdesivir9/12 (75)7/10 (70)Tocilizumab3/12 (25)0/10 (0)Antibiotics8/12 (66.7)8/10 (80)Consequences of Disease – No./Total No. (%)Acute respiratory distress syndrome5/12 (41.7)6/10 (60)Non-ST-elevation myocardial infarction1/12 (41.7)5/10 (50)aIQR: interquartile rangebFor 4 of the deceased individuals, days from symptom onset was unknown.cFor half of the recovered individuals, viral load measurements were not available. To profile the SARS-CoV-2-specific humoral immune response, we performed systems serology to determine the biophysical and functional characteristics of SARS-CoV-2-specific antibodies that recognize the SARS-CoV-2 S, the S-derived receptor-binding domain (RBD), and N. Titers of SARS-CoV-2-specific isotypes and subclasses, Fcγ-receptor binding profiles, neutralization, as well as antigen-specific innate effector functions were measured. Heterogeneous responses were observed across both populations (Figure 1A; Figure S2), and convalescents did not appear to possess quantitatively superior immune responses that could explain their different later disease course. Univariate analyses further confirmed that no significant differences were observed in SARS-CoV-2-specific immunoglobulin G1 (IgG1) or IgA1 titers across S, RBD, and N (Figures 1B and 1C; Figure S2). Conversely, subtle distribution differences were observed for SARS-CoV-2-specific IgM responses, with a slight shift toward higher S-specific IgM among survivors and a trend toward increased N-specific IgM responses among individuals who died (Figure 1C). Functional antibody profiles displayed similar distributions across the cohorts for antibody-dependent cellular phagocytosis (ADCP) (Figure 1D) and neutralization (Figure 1G). Surprisingly, RBD-specific, antibody-mediated natural killer (NK) cell degranulation (NKD) and antibody-dependent neutrophil phagocytosis (ADNP), both driven by the related Fcγ-receptors FcγR3A and FcγR3B, respectively, trended toward increases among individuals who died (Figures 1D–1F). Antibody measurements were influenced minimally by time since symptom onset (Figure S1), suggesting equivalent evolution of humoral immune responses across groups. However, no single antibody feature could discriminate between the groups.Figure 1Heterogeneity in Antibody Responses across SARS-CoV-2 Antigens in Individuals Who Recover or Pass Away22 plasma samples from SARS-CoV-2 infected individuals were profiled at the time of hospitalization against SARS-CoV-2 S, RBD, and N antigens.(A) The heatmap shows the humoral immune responses across individuals who later passed away (deceased) or recovered (convalescent). The heatmap is split by SARS-CoV-2 S, RBD, and N